Continuous Isomaltulose Intake for Postprandial Arterial Stiffness
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Postprandial hyperglycemia due to meals high in carbohydrates increases arterial stiffness, a risk factor for cardiovascular disease, and existing solutions fail to inhibit this increase effectively.
Innovation Solution
Continuous administration of isomaltulose for at least 4 weeks inhibits the rise in arterial stiffness following glucose ingestion, using isomaltulose as an active ingredient.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Use of energy by moving object
If glucose is loaded to provide energy, then blood glucose level increases, but arterial stiffness increases
Solution Approach 1:
Isomaltulose is administered before glucose load to prepare the vascular system. The continuous ingestion over 4 weeks or more creates a preliminary protective effect that prevents the harmful increase in arterial stiffness that would normally occur after glucose ingestion, without preventing the beneficial glucose utilization for energy.
Solution Approach 2:
Isomaltulose acts as an intermediary substance between glucose ingestion and the vascular system. It modulates the metabolic response to glucose, preventing the direct harmful effect of glucose load on arterial stiffness while still allowing glucose to be used for energy production.
2Object-affected harmful factors
If existing inhibitors are used to reduce arterial stiffness, then some improvement is achieved, but they cannot inhibit increase in arterial stiffness under glucose load
Solution Approach 1:
The invention changes the temporal parameter of administration from acute/single-dose to chronic/continuous ingestion (4 weeks or more). This parameter change transforms isomaltulose from a simple sugar into a substance that produces long-term adaptive effects on the vascular system, enabling it to protect against arterial stiffness increase even during acute glucose challenges.
Data Source
Figure 1(a)~1(d)
Figure 2(a)~2(d)
AI summary
The present invention relates to an inhibitor of an increase in arterial stiffness containing isomaltulose as an active ingredient, wherein the inhibitor of an increase in arterial stiffness is used such that the isomaltulose is continuously administered to a human once or more a day for 4 weeks or more.